OBJECTIVES: To assess the health related quality of life (HRQoL) and the change in the NYHA class after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the management of stable coronary artery disease (CAD). The study was non-randomized. CABG group consisted of 240 patients and 229 patients were treated with PCI. HRQoL was measured prospectively by the 15D instrument. RESULTS: Three-year survival was 95.0 and 95.6% (NS). The HRQoL improved statistically in both groups until 6 months after treatment but deteriorated towards the end of the follow-up of 36 months. Clinically evident improvement of the HRQoL and decrease of the NYHA class took place more frequently among CABG patients. CONCLUSIONS: Despite initially more serious preoperative state and more demanding procedure CABG patients achieve equal level of HRQoL when compared with PCI patients. CABG patients may also obtain better relief from symptoms in mid-term follow-up. HRQoL cannot be the only factor to determine outcome after invasive treatment of CAD but it has to be placed in the context of the overall situation.
OBJECTIVES: To assess the health related quality of life (HRQoL) and the change in the NYHA class after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the management of stable coronary artery disease (CAD). The study was non-randomized. CABG group consisted of 240 patients and 229 patients were treated with PCI. HRQoL was measured prospectively by the 15D instrument. RESULTS: Three-year survival was 95.0 and 95.6% (NS). The HRQoL improved statistically in both groups until 6 months after treatment but deteriorated towards the end of the follow-up of 36 months. Clinically evident improvement of the HRQoL and decrease of the NYHA class took place more frequently among CABG patients. CONCLUSIONS: Despite initially more serious preoperative state and more demanding procedure CABG patients achieve equal level of HRQoL when compared with PCI patients. CABG patients may also obtain better relief from symptoms in mid-term follow-up. HRQoL cannot be the only factor to determine outcome after invasive treatment of CAD but it has to be placed in the context of the overall situation.
Authors: Barbora Silarova; Iveta Nagyova; Jaroslav Rosenberger; Martin Studencan; Daniela Ondusova; Sijmen A Reijneveld; Jitse P van Dijk Journal: Qual Life Res Date: 2012-01-10 Impact factor: 4.147
Authors: Eeva M Ryhänen; Ilkka Heiskanen; Harri Sintonen; Matti J Välimäki; Risto P Roine; Camilla Schalin-Jäntti Journal: Endocr Connect Date: 2015-07-08 Impact factor: 3.335
Authors: Jelena Stevanović; Petros Pechlivanoglou; Marthe A Kampinga; Paul F M Krabbe; Maarten J Postma Journal: PLoS One Date: 2016-03-24 Impact factor: 3.240
Authors: Tom H Oreel; Pythia T Nieuwkerk; Iris D Hartog; Justine E Netjes; Alexander B A Vonk; Jorrit Lemkes; Hanneke W M van Laarhoven; Michael Scherer-Rath; Mirjam A G Sprangers; José P S Henriques Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240
Authors: Jarno Kotajärvi; Anna-Maija Tolppanen; Juha Hartikainen; Heikki Miettinen; Marketta Viljakainen; Janne Martikainen; Risto P Roine; Piia Lavikainen Journal: PLoS One Date: 2022-04-01 Impact factor: 3.240